$29.06
0.341.18%
At close: -
$29.84
0.782.68%
After Hours: 6:49 PM EDT
Comments
Loading...
Kiniksa Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:KNSA | Benzinga
Kiniksa Pharmaceuticals International PLC has a consensus price target of $37.14 based on the ratings of 7 analysts. The high is $45 issued by Jefferies on April 29, 2025. The low is $32 issued by Goldman Sachs on July 26, 2023. The 3 most-recent analyst ratings were released by Jefferies, Wedbush, and Citigroup on April 29, 2025, April 16, 2025, and March 13, 2025, respectively. With an average price target of $39.67 between Jefferies, Wedbush, and Citigroup, there's an implied 32.93% upside for Kiniksa Pharmaceuticals International PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
Wedbush
Citigroup
JP Morgan
Evercore ISI Group
1calculated from analyst ratings
Analyst Ratings for Kiniksa Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/29/2025 | Buy Now | 50.8% | Jefferies | Roger Song34% | $40 → $45 | Maintains | Buy | Get Alert |
| 04/16/2025 | Buy Now | 13.94% | Wedbush | David Nierengarten60% | $34 → $34 | Reiterates | Outperform → Outperform | Get Alert |
| 03/13/2025 | Buy Now | 34.05% | Citigroup | Geoff Meacham72% | → $40 | Initiates | → Buy | Get Alert |
| 11/05/2024 | Buy Now | 34.05% | JP Morgan | Anupam Rama59% | $39 → $40 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | 17.29% | Evercore ISI Group | Liisa Bayko71% | $30 → $35 | Maintains | Outperform | Get Alert |
| 09/13/2024 | Buy Now | 34.05% | Jefferies | Roger Song34% | → $40 | Initiates | → Buy | Get Alert |
| 07/23/2024 | Buy Now | 13.94% | Wedbush | David Nierengarten60% | $30 → $34 | Maintains | Outperform | Get Alert |
| 05/03/2024 | Buy Now | 13.94% | Wells Fargo | Eva Fortea Verdejo27% | → $34 | Initiates | → Overweight | Get Alert |
| 05/01/2024 | Buy Now | 0.54% | JP Morgan | Anupam Rama59% | $26 → $30 | Maintains | Overweight | Get Alert |
| 04/24/2024 | Buy Now | 0.54% | Evercore ISI Group | Liisa Bayko71% | $25 → $30 | Maintains | Outperform | Get Alert |
| 01/02/2024 | Buy Now | -16.22% | Wedbush | David Nierengarten60% | $23 → $25 | Maintains | Outperform | Get Alert |
| 07/26/2023 | Buy Now | 7.24% | Goldman Sachs | Paul Choi60% | $22 → $32 | Maintains | Buy | Get Alert |
| 03/09/2023 | Buy Now | -32.98% | JP Morgan | Anupam Rama59% | $19 → $20 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Kiniksa Pharmaceuticals (KNSA) stock?
The latest price target for Kiniksa Pharmaceuticals (NASDAQ:KNSA) was reported by Jefferies on April 29, 2025. The analyst firm set a price target for $45.00 expecting KNSA to rise to within 12 months (a possible 50.80% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kiniksa Pharmaceuticals (KNSA)?
The latest analyst rating for Kiniksa Pharmaceuticals (NASDAQ:KNSA) was provided by Jefferies, and Kiniksa Pharmaceuticals maintained their buy rating.
When was the last upgrade for Kiniksa Pharmaceuticals (KNSA)?
There is no last upgrade for Kiniksa Pharmaceuticals
When was the last downgrade for Kiniksa Pharmaceuticals (KNSA)?
There is no last downgrade for Kiniksa Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Kiniksa Pharmaceuticals (KNSA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiniksa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiniksa Pharmaceuticals was filed on April 29, 2025 so you should expect the next rating to be made available sometime around April 29, 2026.
Is the Analyst Rating Kiniksa Pharmaceuticals (KNSA) correct?
While ratings are subjective and will change, the latest Kiniksa Pharmaceuticals (KNSA) rating was a maintained with a price target of $40.00 to $45.00. The current price Kiniksa Pharmaceuticals (KNSA) is trading at is $29.84, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
